The PeptideChat Blog

Weekly features, the hottest new peptides, vendor spotlights, and beginner-friendly guides.

Peptide of the Week

Peptide of the Week: Retatrutide's Phase 3 Data Lands — And So Does a Delay

TRIUMPH-1 recorded 28.3% average weight loss at 80 weeks, the largest ever in a phase 3 obesity trial. Then Lilly pushed its FDA filing to Q1 2027. Both halves of that story matter, and so do the numbers underneath the headline.

Read article
Vendor Spotlight

The Certificate of Analysis Named the Wrong Drug

A 2026 investigation found retatrutide sold over the counter in Brooklyn bodegas, a 265% jump in poison-center calls, and a lab certificate that appeared to describe a different peptide than the one on the label. Here's what that teaches about reading a COA.

Read article
Guide

The FDA Just Voted on BPC-157, TB-500 and Five More Peptides. Here's What Actually Happened.

On July 23-24, 2026, an FDA advisory committee voted to recommend six of seven peptides for legal compounding — over the objections of the FDA's own reviewers. Nothing has legally changed yet, and the details matter more than the headlines.

Read article
Hottest Peptides

Amylin Is the New Frontier: Inside the Class That Took Over ADA 2026

Cagrilintide, zenagamtide and petrelintide made this June's diabetes meeting an amylin meeting. The pitch is GLP-1-like results with dramatically better tolerability — and the early data is doing more than hinting at it.

Read article
Guide

GH Secretagogues Explained

A research-focused look at the two main classes of growth-hormone secretagogues — GHRH analogs and ghrelin mimetics — how they differ, and why scientists study them in combination.

Read article
Guide

Peptides 101: A Beginner's Guide

A friendly, science-forward introduction to what peptides are, how they differ from proteins, the major research categories, and how they're studied — written for the curious newcomer.

Read article
Vendor Spotlight

How to Vet a Peptide Research Vendor

A neutral, science-forward checklist for evaluating research-peptide suppliers — covering third-party testing, certificates of analysis, purity data, storage, reputation, and the legal "research use only" context.

Read article
Hottest Peptides

The Hottest New Peptides Right Now

A research-focused tour of 2026's most talked-about peptides, from the GLP-1/GIP/glucagon weight-loss wave to emerging longevity and cellular-repair compounds like MOTS-c and SS-31.

Read article
Stack of the Week

Stack of the Week: The Wolverine Stack

A look at the popular "Wolverine" stack — BPC-157 paired with TB-500 — and why these two peptides are so often discussed together in recovery research. Educational only; not medical or dosing advice.

Read article
Peptide of the Week

Peptide of the Week: BPC-157

BPC-157, the so-called "Body Protection Compound," is one of the most talked-about research peptides for tissue and gut healing. Here's what it is, how it's thought to work, and why it sparks so much curiosity.

Read article

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.